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Background: The management of rectal cancer (RC) has substantially changed over the last decades with the
implementation of neoadjuvant chemoradiotherapy, adjuvant therapy and improved surgery such as total
mesorectal excision (TME). It remains unclear in which way these approaches overall influenced the rate of local
recurrence and overall survival.
Methods: Clinical, histological and survival data of 658 out of 662 consecutive patients with RC were analyzed for
treatment and prognostic factors from a prospectively expanded single-institutional database. Findings were then
stratified according to time of diagnosis in patient groups treated between 1993 and 2001 and 2002 and 2010.
Results: The study population included 658 consecutive patients with rectal cancer between 1993 and 2010.
Follow up data was available for 99.6% of all 662 treated patients. During the time period between 2002 and 2010
significantly more patients underwent neoadjuvant chemoradiotherapy (17.6% vs. 60%) and adjuvant chemotherapy
(37.9% vs. 58.4%). Also, the rate of reported TME during surgery increased. The rate of local or distant metastasis
decreased over time, and tumor related 5-year survival increased significantly with from 60% to 79%.
Conclusion: In our study population, the implementation of treatment changes over the last decade improved the
patient’s outcome significantly. Improvements were most evident for UICC stage III rectal cancer.
Keywords: Rectal cancer, Improved survival, TMEBackground
Colorectal cancer (CRC) is the second leading cancer in
the western world, accounting for about 500,000 deaths
annually worldwide [1]. About half of the CRC are lo-
cated in the rectum [2,3]. Rectal carcinoma (RC) has
been considered and treated as an independent disease
due to its primarily extra peritoneal location, the po-
tential, impairment of anorectal continence and the* Correspondence: wiegering_a@ukw.de
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article, unless otherwise stated.differences in metastatic behavior. Over the last decades
numerous studies extensively investigated different treat-
ment options in chemo-, radio-, chemoradiotherapy and
surgery to improve the outcome, leading to significant
changes in the management of RC [4,5].
Today the treatment can be divided in four phases:
First, the preoperative diagnostic phase with the staging
based on rectoscopy, endosonography, MRI and CT
scan, followed by a second phase of neoadjuvant therapy
for locally advanced and nodal-positive cancer in the
middle and lower rectum [6,7]. The third phase consists
of surgical removal of the cancer, which is performed by
central ligation of the lower mesenteric vessels, systemic
lymph-node dissection and rectal resection including thetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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consists of adjuvant therapy depending on the definitive
histopathological stage with 5-fluorouracil, leucovorin and
oxaliplatin [12,13]. In the fifth phase, multimodal chemo-
therapy and/or resection of metastases are performed if
recurrent disease is detected during a structured follow-
up [14-16].
While each individual modification of the disease man-
agement has been described in detail with respect to its
specific effect and clinical outcome, little is known about
the synergistic effects of all modifications together. The
presumed additive effect has led to multimodal treat-
ment suggestions in the current guidelines (NCIE CG131
(http://www.nice.org.uk/guidance/CG131); NCCN rectal
cancer (http://www.nccn.org); ESMO (http://www.esmo.
org); AWMF (www.AWMF.de)). Recently also the European
consensus guidelines for treatment of patients with colo-
rectal cancer has been published to achieve an equivalent
treatment for patients across Europe and to address open
questions [17].
We performed a single center retrospective analysis of
patients with rectal cancer from 1993 to 2010. The aim
was to compare how the combination of multi factorial
changes has improved the cancer-related outcome in
terms of local recurrence, distant metastasis and survival.
Methods
Patient population
All patients with rectal cancer treated at the University of
Wuerzburg Medical Centre (UKW) between January 1993
and December 2010 were chosen from the Wuerzburg
Institutional Database (WID). Patients were grouped into
categories according to the time of diagnosis (January
1993 to December 2001 and January 2002 and December
2010).
Data source
The WID is a central data repository that has been ex-
panded on a daily basis since 1984 with clinical, operative
and research data of patients who were evaluated and
treated at the UKW. Data available within the WID in-
clude patient demographics, histological diagnoses based
on International Classification of Diseases coding stan-
dards, physician data, inpatient admission and outpatient
registration data, operative procedures, laboratory results
and computerized pharmacy records. Continuous cross
platform integration with the Wuerzburg Comprehensive
Cancer Registry ensures updated follow-up information
for identification of deceased patients. Inpatient and out-
patient records of all identified patients were reviewed
retrospectively to extract information regarding type and
duration of chemotherapy, sites of metastatic disease at
presentation and disease status at last follow-up. Missing
data were retrieved from patient case notes when possible.Demographic details, along with clinical data at the
time of primary diagnosis and during the surgery (tumor
site and the presence of metastases) as well as histologic
results (tumor (T) stage, nodal (N) stage, tumor differen-
tiation (G) and evidence of microscopic venous (V) and
lymphatic vessel invasion (L)) were correlated with sur-
vival data obtained from prospective follow-up registry.
Follow-up
Postoperative follow-up consisted of quarterly outpatient
assessments or gathering complete information from the
patient’s primary care physician in 3-month intervals, for
10 years. After 10 years, information was obtained on an
annual basis retrospectively. Depending on the posto-
perative staging, follow-up included abdominal ultra-
sound at 3, 6, 12 and 18 months and after that on a
yearly basis. Computed tomography and surveillance
colonoscopy were routinely performed 3 to 6 months
after the resection and repeated every year. After 5 years,
no structured follow-up was performed and diagnostic
tests where based on symptoms or incidental findings.
Ethics
The University of Wurzburg ethics committee has ap-
proved this study for full ethics waiver due to its retro-
spective and anonymised nature. The head of the board
for internal data requests, Dr. U. Maeder granted per-
mission to access data from the registry.
Statistical analysis
The data were analyzed with statistical software set up
in Linux by an-house biostatistician (M.U.). Clinical and
histological parameters were compared with the Mann–
Whitney U or Kruskal–Wallis test for continuous data
and with the χ2 test for categorical variables. P < 0.05
was considered statistically significant. Cox proportional
hazard modeling or ‘Cox regression’ was used for multi-
variate testing [18,19]. Survival curves were drawn ac-
cording to Kaplan–Meier methods.
Results
Patient cohort, demographics and tumor stage
From January 1993 until December 2010 a total of 662 pa-
tients were diagnosed with rectal cancer; only 4 patients
(0.6%) had to be excluded from further analysis secondary
to missing follow-up data. The remaining cohort consisted
of 426 men and 232 women, with an average age of
66 years (+/− 11.7). 301 of these patients were diagnosed
before 2002, 357 between January 2002 and December
2010. Tumors located in the distal 4 cm from the anal
verge increased from 19.6% to 33.9% (p < 0.001). In con-
trast, tumors located 8-12 cm from the anal verge de-
creased from 34.6 to 22.7% (p < 0.001). Whereas the
pathological UICC stage (post surgical therapy) did not
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cUICC stage differed significantly and shifted towards
more advanced disease. Patients with cUICC stage III in-
creased from 23.3% to 37.8% (p < 0.001). Also, patients
with cT3&4 increased from 59.5% to 69.5% (p = 0.007) and
cN + from 30.2% to 51.0% (p < 0.001). The post-resection
pathological examination, in the more recent period bet-
ween 2002 and 2010 revealed an overall reduced tumor
size and significantly less tumor-infiltrated lymph nodes
(p = 0.005). The comparison of limited (pUICC 0;I;II) to
advanced tumor stage (pUICC III; IV) showed that signifi-
cantly more patients were in pathological limited stage
during the second time period (p = 0.048).
Demographics, tumor stage and size, tumor localization
and lymph node status are summarized in Table 1.
Therapeutic management
Overall the proportion of patients undergoing any ad-
ditional therapy to surgery (neoadjuvant and adjuvant) in-
creased over time. For neoadjuvant treatment the rate
increased from 17.6% to 60%. Neoadjuvant radiotherapy
(RT) independent of the protocol (short term 5×5Gy
or long term 25×1.8Gy), doubled from 12% to 23.3%
(p = 0.011). However, changes were most prominent for
neoadjuvant chemoradiotherapy (RCT), which increased
from 5.3% to 35.3% (p < 0.001). When analyzing the
changes in neoadjuvant treatment they were most pro-
minent for patients in clinical stage cUICC II/III. The per-
centage of patients without any preoperative treatment in
this group dropped from 71.8% in the first time frame to
15.7%. While the proportion of patients undergoing ra-
diotherapy alone more then doubled from 20.4% to
50.0% (p < 0.001), patients undergoing chemoradiotherapy
increased even more by five times from 7,0% to 34.3%
(p < 0.001) (Tables 2 and 3). When comparing patients in
the clinical cUICC stage I there was no difference in the
proportion of patients receiving neoadjuvant treatment
(2.5% vs. 5.1%; p = n.s.). Neoadjuvant radiochemotherapy
resulted in 11.9% of patients with a complete pathological
response, 73.3% of these patients had been in clinical UICC
stage III previous to neoadjuvant treatment. Still more than
20% of all patients did not receive preoperative treatment
in the later time period, which was either secondary to pa-
tient refusal or to tumors located above 12 cm from the
anal verge in 7% of all rectal cancers who were not enrolled
in neoadjuvant treatment.
Also significantly more patients underwent any adju-
vant treatment in the second time period (38% vs. 58%,
p < 0.001). Whereas adjuvant radiation therapy alone
(6.3% vs. 2.2% p = 0.009) or in combination with chemo-
therapy (11.0% vs. 5.9% p = 0.02) was more common be-
tween 1993 and 2001, the rate of adjuvant chemotherapy
increased three-fold in the second period from 16% to
45.3% (p < 0.001) (Table 3).For adjuvant treatment in pUICC stage III the percent-
age of patients receiving any therapy did not change signifi-
cantly, whereas the distribution shifted from radiotherapy
with (29% vs. 11.4% p = 0.008) or without chemotherapy
(8.1% vs. 1.3% p = 0.047) (total 37.1% vs. 12.7% p < 0.001)
towards chemotherapy only (22.6% vs. 53.2% p < 0.001).
Differences were more pronounced in stage pUICC II: in
the first time period 22% of all patients received chemo or
chemoradiotherapy, whereas it was 67% in the second
period (p < 0.001).
Overall, more than 90% of the patients underwent any
form of surgical intervention (resection or extirpation)
(92% vs. 91.6%). The proportion undergoing low anterior
rectum resection increased from 59.5% to 64.1% (p < 0.001)
whereas patients undergoing rectum extirpation decreased
(22.3% to 18.2%; n.s.). The rate of patients undergoing
transanal resection increased slightly from 4% to 7.6%.
Also, the rate of patients receiving enterostomy increased
from 64.8% to 75.1% (p = 0.004). TME was reported for
only two patients before 2002, whereas in the second time
period TME was documented in 124 patients (34.7%,
p < 0.001; Table 4).
Recurrence rate
A significantly lower rate of tumor recurrence (local and
metastatic) was found in the second period (Figure 1A).
Five-year recurrence rate was 32% in the first period,
whereas it was 19% between 2002 and 2010 (p = 0.0035).
The five-year local recurrence rate decreased from 14.3%
to 5.3% after 2002 (Figure 1B). In addition, a decreased
five-year distant metastasis was observed (25,5% to
15,2%; p < 0.015). (Figure 1C). When preforming a stage-
by-stage analysis for the occurrence of distant metasta-
sis, especially patients in UICC stage III had a significant
lower 5 year rate in the second time period (40.8% vs
17.5% p = 0.0075). Comparing the neoadjuvant and adju-
vant treatment for this subgroup, in the second time-
frame patients were more commonly treated with
neoadjuvant radio- (17.7% vs 37.7% p = 0.01) or ra-
diochemotherapy (5.2% vs. 39% p < 0.001) whereas adju-
vant treatment was not significantly different (data not
shown). To determine the effect of radiotherapy or ra-
diochemotherapy an analysis independent of the time-
frame was performed. The five-year distant metastasis
rate differed significantly from 39.1% for patients with-
out any treatment, to 22.1% for patients with radiothe-
rapy only and 7.3% for patients with radiochemotherapy
(p = 0.028).
Treatment of metastatic disease
During the first period, 38 out of 67 patients with stage
UICC IV had synchronous liver metastasis only. Three
patients (7.9%) underwent liver resection. Two remained
without recurrent disease. In the later period, 39 out of
Table 1 Characteristics of 658 patients treated between 1993–2010 for rectal cancer at the University hospital of
Wuerzburg
Characteristic 1993-2001 (n=301) 2002..2010 (n=357) p-value
No. % No. %
Sex 0.035
Male 182 244
Female 119 113
Age, years n.s.
Median 66.16 (+/−11.88) 66.83 (+/−11.5)
Range 22.06-93.6 27.7-93.6
pUICC
0 0 0 15 4.2 <0.0001
I 95 28.6 127 35.6 n.s.
II 58 19.3 67 18.8 n.s.
III 62 20.6 79 22.1 n.s.
IV 67 22.3 64 17.9 n.s.
X 19 6.3 5 1.4 <0.001
cUICC
I 81 26.9 79 22.1 n.s.
II 75 24.9 69 19.3 n.s.
III 67 22.3 135 37.8 <0.001
IV 66 21.9 69 19.3 n.s.
X 12 4 5 1.4 0.037
Patho. T-stage
pT0 0 0 18 5 <0.001
pT 1,2 118 39.2 163 45.7 n.s.
pT3 124 41.2 129 36.1 n.s.
pT4 29 9.6 13 3.6 0.002
pTx 30 10 30 8.4 n.s.
pTis 0 0 3 0.8 n.s.
Patho. N-stage
pN0 149 49.5 216 60.5 0.005
pN1 52 17.3 65 18.2 n.s.
pN2 61 20.2 38 10.6 <0.001
pNx 39 13 37 10.4 n.s.
Distance to anal verge
<4cm 59 19.6 121 33.9 <0.001
4-8cm 96 31.9 129 36.1 n.s.
8-12cm 104 34.6 81 22.7 <0.001
>12cm 36 12 24 6.7 0.02
x 6 2 1 0.5 0.033
Clinical T-stage
cT1,2 95 31.6 81 22.7 0.01
cT3,4 179 59.5 248 69.5 0.007
cTx 27 9 28 7.8 n.s.
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Table 1 Characteristics of 658 patients treated between 1993–2010 for rectal cancer at the University hospital of
Wuerzburg (Continued)
Clinical N-stage
N0 140 46.5 128 35.9 0.006
cN+ 91 30.3 182 51 <0.001
cNx 70 23.2 47 13.2 <0.001
Wiegering et al. BMC Cancer 2014, 14:816 Page 5 of 10
http://www.biomedcentral.com/1471-2407/14/81664 patients had synchronous liver metastasis only. 12 pa-
tients (30.8%) underwent liver resection and 6 developed
recurrent diseases. (Rate of liver resection p = 0.011)
During follow up of patients diagnosed before 2002
(n = 234), 31 developed metachronous liver metastases
and 9 underwent liver resection. In contrast, out of the
293 patients diagnosed from 2002–2010, 20 patients de-
veloped liver metastasis. In this cohort, 12 (60%) under-
went liver resection (p = 0.028) (Table 5).
Survival
The overall survival rate improved significantly in pa-
tients who were diagnosed between 2002 and 2010
(5 year 60.5% vs. 79.8% p < 0.0001) (Figure 2). When
comparing patients according to the stage at diagnosis,
those in UICC I did not show any differences between
both time periods. Interestingly, all other patients (UICC
stage II, III and IV) demonstrated a significantly im-
proved survival (Figure 3A-D).
Multivariate testing
In a multivariate analysis of epidemiological and clinical
features, presence of distant metastases (HR = 3,627, CI:
1,338-9,833, P = 0.011), presence of locoregional lymph
node metastases (HR: 2.38; CI:1.49-3.82, P < 0.001) and
decade of tumor incidence (HR = 2.280, CI: 1,649 -
3,153, P < 0.001) were independent predictors of tumor-
related death.
Discussion
By analyzing the patient treatment and outcome from a
prospective institutional based database (WID) we found
a significantly improved survival of patients treated for
rectal cancer in the last two decades. This was eminent
and therefore attributable to patients who were treated
with newly implemented strategies for rectal cancer.
Major changes as neoadjuvant radiochemotherapy andTable 2 Percentage of neoadjuvant therapy performed in eac
Neoadjuvant-Therapy in clinical stage 1993-2001 (n=14
cUICC II/III No.
No 102
Chemo 1
Radio 29
Radiochemo 10TME have been introduced at our institution between
1999–2003. Consequently, improvements in outcome
comparing the time periods between 1993–2001 with
2002–2010 were to be expected. Unfortunately we can-
not attribute the improved survival directly to special
change in treatment. It seams very likely to be an ad-
ditional and potentially synergistic effect of improved
surgery, neoadjuvant and adjuvant treatment rather than
coexistence of the several effects.
Historically, surgical resection for rectal cancer has
been burdened by a high local recurrence rate and con-
comitant or consecutive distant metastatic disease re-
sulting in a moderate 5-year survival rate. With progress
in surgical technique, supportive management and new
insights in the understanding of oncological principles
improved outcome was observed [20]. Especially in the
last two decades, the therapeutic management has chan-
ged dramatically in terms of pre- and postoperative
treatment, as well as surgical strategy. Each individual
change has demonstrated advantages in terms of out-
come (survival, recurrence etc.) or quality of life (sphinc-
ter preservation, fecal continence, etc.).
To our knowledge, this is the first study comparing
survival and recurrence rates including all implemented
changes over the past two decades, rather than focusing
on a single aspect in the change of management in a
large case series with over 600 patients. We have deli-
berately included all patients, irrespective of cancer
stage, age or treatment intention to reflect the clinical
daily live reality in this cancer. Since this is a longitu-
dinal study of a single institution within the same region,
a selection bias by massive socioeconomic changes in
the study population appears to be unlikely.
We observed a significant shift towards more patients
with clinical stage UICC III and less clinical stage UICC
II, probably due to a more detailed diagnostic work-up
via MRI and endoluminal ultrasound in the second timeh time period in clinical stage UICC III patients
2) 2002. 2010 (n=204) p-value
% No. %
71.8 32 15.7 <0.001
0.7 0 0 n.s.
20.4 102 50.0 <0.001
7.0 70 34.3 <0.001
Table 3 Percentage of neoadjuvant and adjuvant therapy
performed in each time period over all patients
Therapy
all patients
1993-2001 (n=301) 2002. 2010 (n=357) p-value
No. % No. %
Neoadjuvant
No 248 82.4 143 40 <0.001
Chemo 1 0.3 3 0.8 n.s.
Radio 36 12 83 23.3 0.011
Radiochemo 16 5.3 126 35.3 <0.001
Unknown 0 0 2 0.6 n.s.
Adjuvant
No 187 62.1 149 41.6 <0.001
Chemo 48 16 162 45.3 <0.001
Radio 19 6.3 8 2.2 0.009
Radiochemo 33 11 20 5.9 0.02
Unknown 14 4.7 18 5.0 n.s.
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underrepresentation of clinical UICC stage III patients
in the first treatment period and thereby leading to a
stage migration in the later time period [23]. However,
stage migration alone can hardly explain the observed
major improvement. This is emphasized by the fact that
that the survival of patients in stage UICC III in the
second timeframe is superior to UICC II in the first
timeframe.Table 4 Type of surgical procedure performed in each
time period over all patients
Characteristics 1993-2001
(n=301)
2002. 2010
(n=357)
p-value
No. % No. %
Operation n.s.
Yes 277 92 327 91.6
No 24 8 30 8.4
No 24 8 30 8.4 n.s.
Anterior resection 179 59.5 167 64.1 <0.001
Extirpation 67 22.3 65 18.2 n.s.
Trans anal excision 12 4 27 7.6 n.s.
Other 19 6.3 6 1.7 0.002
TME/PME reported <0.001
Yes 2 0.7 124 34.7
No 299 99.3 233 65.3
Stoma 0.004
Yes 195 64.8 268 75.1
No 88 29.2 66 18.5
Not reported 18 6 23 6.4When analysing post-operative T and N stage separately,
patients with T1/T2 and the proportion of nodal negative
cancer had increased significantly. Also, comparing the ra-
tio of histologically advanced cancer (pUICC III and IV)
to limited cancer (pUICC 0, I and II) showed a significant
shift towards limited cancer. Since there is no biological
explanation why patients in the second time period should
have different tumor stages, the shift toward lower patho-
logical tumor stages could be attributed to the effects of
neoadjuvant treatment, in the second time period or ear-
lier diagnostic detection.
The effect of neoadjuvant radiochemotherapy is also
supported by the fact that in the second time period a
complete histopathological response was observed in
11.9% of neoadjuvant radiochemotherapy treated pa-
tients. This is in line with published complete response
rate between 10 to 30% [24].
The better survival and reduced recurrence rate is not
observed for patients with UICC stage I, with only a
slight improvement in overall survival, which was not
significant. This reflects the fact that introduced changes
were not applied for UICC stage I patients. UICC stage I
did not undergo perioperative radio-chemotherapy. Also
introduction of TME was reported not to change local
recurrence rate, distant recurrence rate or overall sur-
vival in UICC stage I patients [25]. Hereby, the group of
UICC stage I patients provides a reference for the pa-
tients with more advanced cancer which showed sig-
nificant changes in treatment and outcome. Also when
comparing a small subgroup of patients in stage UICC
III in both time periods, who did not receive pre- and or
postoperative radio-chemotherapy and TME, no dif-
ference in cancer-related survival was observed. This
supports the notion that the improved survival in other
patient populations can be attributed to the imple-
mented therapeutic changes.
The most prominent survival increase was noted in pa-
tients stage UICC III. This group received preoperative
treatment in a significant higher percentage since 2002
(24 vs. 77%). In addition to the rate also the modality of
neoadjuvant treatment changed: In the early period more
patients received radiation therapy alone (20% radio-
therapy vs. 5% chemoradiotherapy) whereas in the second
period around 78% received radio- or chemoradiotherapy
(36% radiotherapy vs. 43% chemoradiotherapy).
The effect of radiotherapy alone probably had a limited
impact on the overall survival and distant metastasis rate
[26,27]. Also in our analysis radiotherapy alone reduced
the occurrence of distant metastasis but did not reach
statistical significance, whereas patients treated with ra-
diochemotherapy demonstrated significantly lower distant
metastasis rates. Therefore, the observed survival im-
provement can be attributed to improved surgery, adju-
vant therapy and neoadjuvant chemoradiotherapy, which
Figure 1 Kaplan-Meir plot showing influence of diagnosis time point on recurrence risk. (A) Total recurrence risk including local recurrence
and distant metastasis, (B) local recurrence rate, (C) distant metastasis rate (1993–2001 blue; 2002–2010 green).
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that adjvant chemotherapy is standard since the early 1990
and the use of 5-FU did not change over time, the
enhanced survival in part could also be referred due to
introduction of new chemotherapeutic agents such as
Oxaliplatin and biological agents [28-30]. The change in
the surgical procedures may also account for the improved
survival. Köckerling et al. showed that the use of TME not
only reduce local recurrence but also improving 5-year
survival rate from 50% to 71% [10]. Similar results were
demonstrated comparing trials using different operative
strategies for rectal cancer resection (CRAB and TME trial)
[25]. Also the introduction of the so-called Holm proced-
ure for abdomino-rectal extirpation with extended resec-
tion margins improved the oncological outcome [31,32].
Several studies have shown that resection of liver me-
tastasis increased the 5-year survival from around 4% up
to 40% [33-37]. In line with this, the rate of patients with
liver metastasis undergoing liver resection increasedTable 5 Number of liver resection due to metachronos liver m
Liver operation in case of
metachron liver metastasis
during 5 year follow up
1993-2001 (n=31 of 234)
No. %
No 22 71
Yes 9 29significant. In addition to the resection of liver metasta-
ses, other factors like resection of pulmonary metastases,
multimodal chemotherapy with targeted therapeutics
and HIPEC therapy account for the five-year survival of
nearly 30% in UICC stage IV patients since 2002.
Compared to distant metastases, local recurrence rate
is probably much more influenced by radiotherapy and
surgical procedure [38]. Local recurrence rate decreased
by ~60% from 14% to 5%, which is in accordance with
published data after the introduction of TME [11] and
neoadjuvant radio chemotherapy [7] in the second time
period. The observed local recurrence rate in the first
time period was 14% which is lower than the about 30%
reported elsewhere for the same time period [10]. This
could be explained by surgical procedures in a TME-like
fashion, which have not been termed as such during the
first time period and the relative high number of pa-
tients undergoing neoadjuvant radiotherapy in the first
treatment period. With TME being the “gold standard”etastasis according to each time period
2002. 2010 (n=20 of 293) p-value
No. %
8 40 0.028
12 60
Figure 2 Kaplan-Meir plot showing relative survival of patients
treated between 1993–2001 (n= 301) and 2002–2010 (n=357)
(1993–2001 blue; 2002–2010 green).
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third of all patients appears very low. However, the item
“TME” in the database was only set to “yes” if TME is
specifically named in the procedure note, most likely
resulting in a documentation bias [8,39-43].Figure 3 Kaplan-Meir plot showing relative survival of patients treate
diagnosis. (A) UICC I (95 vs. 127) (B) UICC II (58 vs.67) (C) UICC III (62 vs.79When comparing our results with the data from the
EUROCARE study which analyzed the progress in sur-
vival of patients with CRC in 16 European countries
from the 1980s to the early 21st century, we observed a
slightly better 5-year survival then the 50-60% reported
in Europe diagnosed between 2000–2002 which could
be attributed to the academic setting of our hospital and
the higher volume [44].
In the presented study the time point of diagnosis ap-
peared as an independent factor for cancer related sur-
vival, despite a significantly higher number of patients
with advanced tumor stages and lymph node metastases
during this time period. This fact makes it over all very
unlikely that the observed change in survival benefit in
the second time period is coincidental.
Conclusion
Survival of patients with stage UICC II-IV rectal cancer
has dramatically improved over the last decade, in terms
of tumor recurrence and patient survival. Our data dem-
onstrates clearly that the current combination-treatment
of perioperative therapy and surgical resection, which is
recommended in the national and international guide-
lines results in significantly enhanced patient outcome
with synergistic effects compared to each individual
change.d between 1993–2001 and 2002–2010 according to UICC stage at
) (D) UICC IV (67 vs. 64) (1993–2001 blue; 2002–2010 green).
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